Mexico. Formulation patents banned from the Linkage Gazette disregarding a Supreme Court’s decision.
Marketing authorization for pharmaceutical products to foreign applicants
por Agustín Azcatl Under the amendment made to the Articles 168 and 170 of the Health Supplies Regulation, about the omission of the requirement for a manufacturing plant, last May 5, 2011, the Mexican Government granted the first Marketing Authorization (drug licensing) through the Health Ministry (The Federal Commission for Protection against Sanitary Risk COFEPRIS) to […]
New registry for security interests
POR RICARDO CADENA MANAGING INTELLECTUAL PROPERTY, DECEMBER 2010 / JANUARY 2011 Enforcing security interests is not always as simple as we may want it to be, especially when it comes to chasing debtors who retain title or possession of secured IP, or any movable asset colateral, where the debtor can assign or set that asset as […]
A practical cross-border insight into merger control
por Gustavo Alcocer & Carlos Woodworth 1 Relevant authorities and legislation 1.1 Who is/are the relevant merger authority(ies)? The Federal Competition Commission, which is an administrative agency independent from the Mexican Ministry of Economy, has technical and operational autonomy to issue its resolutions. The Commission is integrated to exercise merger authority by public officials, divisions and administrative […]
New register against counterfeits
Approval of follow-on biologics in Mexico
por Armando Arenas y Juan Luis Serrano The Mexican General Health Law was reformed on 11th June 2009 to include Article 222bis, which defined biotechnological drugs and allowed for the approval of so-called “biocomparables”. The decree came into force on 8th September 2009 and the Ministry of Health had a 180-day period to issue all the specific regulations pertaining […]
Global Pharmaceutical Linkage Regulations: A Proposed Analytical Framework
POR JUAN LUIS SERRANO Prompt and affordable access to essential medicines is a component of almost all domestic and global public health models. As is now well known, the availability and costs of both brand and generic drugs is a function of traditional patent law incentives. Less known, however, is that generic entry is controlled increasingly […]
Patent Prosecution Highway in Mexico
Managing Intellectual Property, April 2011 There is good news for applicants in Mexico of patents claiming Paris Convention priority or PCT applications. As of March 1st, 2011, the Mexican Patent and Trademark Office launched a pilot program whereby they Patent Department will accept as valid the examination carried by an Examiner of the United States Patent […]